Hee-Jae Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hee-Jae Jung has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Eun-Jae Lee
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea
2 shared publications - Hyunjin Kim
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Young-Min Lim
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Bum Joon Kim
Department of Neurology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea
1 shared publication Byoung Joon Kim
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
1 shared publication- Do Yun Kwon
Department of Aviation Medical Squadron, Republic of Korea Air Force, Daegu, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 13 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5637-5648
Optimising the Therapeutic Window: A Systematic Review and Network Meta‐Analysis of Pregabalin Dosing Strategies for Painful Diabetic Neuropathy
Aims: Although pregabalin is a first‐line therapy for painful diabetic polyneuropathy (PDPN), its optimal dose–response relationship remains unclear. We conducted a network meta‐analysis to evaluate the efficacy and safety of fixed pregabalin dosages in PDPN patients. Materials and Methods: We systematically searched major databases through October 2025 comparing various doses of pregabalin (75, 150, 300, and 600 mg/day) with placebo in adults with PDPN. The outcomes were short‐ and long‐term changes in the average daily pain score, patient/clinician global impression of change, and adverse events (AEs) including dizziness, somnolence, headache, and peripheral oedema. Results: Twelve RCTs were eligible. In the short term, pregabalin 300 (Standardised Mean Difference [SMD], 1.09; 95% CI, 0.69–1.50) and pregabalin 600 mg/day (SMD, 0.90; 95% CI, 0.24–1.55) produced significant pain reduction compared with placebo. In the long term, both pregabalin 300 (SMD, 0.12; 95% CI, 0.06–0.17) and 600 mg/day (SMD, 0.31; 95% CI, 0.23–0.38) remained effective, whereas pregabalin 75 and 150 mg/day did not demonstrate superiority over placebo. Regarding safety, both pregabalin 300 and 600 mg/day were associated with greater risks of dizziness, somnolence, and peripheral oedema compared with pregabalin 75 mg/day, pregabalin 150 mg/day, and placebo. Conclusion: Pregabalin doses ≤ 150 mg/day demonstrated no clinical benefit over placebo. Conversely, both pregabalin 300 and 600 mg/day showed a pain reduction effect at short‐ and long‐term follow‐up. Given that pregabalin 600 mg/day was associated with a higher incidence of AEs, pregabalin 300 mg/day appears to offer a more favourable balance, aligning potent efficacy with a manageable safety profile.
- 13 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5637-5648
Open AccessOptimising the Therapeutic Window: A Systematic Review and Network Meta‐Analysis of Pregabalin Dosing Strategies for Painful Diabetic Neuropathy
Aims: Although pregabalin is a first‐line therapy for painful diabetic polyneuropathy (PDPN), its optimal dose–response relationship remains unclear. We conducted a network meta‐analysis to evaluate the efficacy and safety of fixed pregabalin dosages in PDPN patients. Materials and Methods: We systematically searched major databases through October 2025 comparing various doses of pregabalin (75, 150, 300, and 600 mg/day) with placebo in adults with PDPN. The outcomes were short‐ and long‐term changes in the average daily pain score, patient/clinician global impression of change, and adverse events (AEs) including dizziness, somnolence, headache, and peripheral oedema. Results: Twelve RCTs were eligible. In the short term, pregabalin 300 (Standardised Mean Difference [SMD], 1.09; 95% CI, 0.69–1.50) and pregabalin 600 mg/day (SMD, 0.90; 95% CI, 0.24–1.55) produced significant pain reduction compared with placebo. In the long term, both pregabalin 300 (SMD, 0.12; 95% CI, 0.06–0.17) and 600 mg/day (SMD, 0.31; 95% CI, 0.23–0.38) remained effective, whereas pregabalin 75 and 150 mg/day did not demonstrate superiority over placebo. Regarding safety, both pregabalin 300 and 600 mg/day were associated with greater risks of dizziness, somnolence, and peripheral oedema compared with pregabalin 75 mg/day, pregabalin 150 mg/day, and placebo. Conclusion: Pregabalin doses ≤ 150 mg/day demonstrated no clinical benefit over placebo. Conversely, both pregabalin 300 and 600 mg/day showed a pain reduction effect at short‐ and long‐term follow‐up. Given that pregabalin 600 mg/day was associated with a higher incidence of AEs, pregabalin 300 mg/day appears to offer a more favourable balance, aligning potent efficacy with a manageable safety profile.
- 29 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 105, 106892
Transverse myelitis following COVID-19 infection or vaccination: Clinical outcomes and imaging characteristics compared with idiopathic cases
- 29 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 105, 106892
Transverse myelitis following COVID-19 infection or vaccination: Clinical outcomes and imaging characteristics compared with idiopathic cases
- 26 August 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2110990
Electrophysiological features of anti-neurofascin-155 autoimmune nodopathy: Preferential involvement of distal and proximal segments
- 26 August 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2110990
Electrophysiological features of anti-neurofascin-155 autoimmune nodopathy: Preferential involvement of distal and proximal segments
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Clinical Neurology
- Vol. 21 (3) , 235-237
Oxaliplatin-Induced Acute Peripheral Nerve Hyperexcitability
Jung HJ, et al. J Clin Neurol. 2025 May;21(3):235-237. https://doi.org/10.3988/jcn.2025.0022
- 1 January 2025
- Published by XMLink in Journal of Clinical Neurology
- Vol. 21 (3) , 235-237
Open AccessOxaliplatin-Induced Acute Peripheral Nerve Hyperexcitability
Jung HJ, et al. J Clin Neurol. 2025 May;21(3):235-237. https://doi.org/10.3988/jcn.2025.0022
- 1 January 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (1) , 14-21
Time Window for Induced Hypertension in Acute Small Vessel Occlusive Stroke With Early Neurological Deterioration
BACKGROUND: Therapeutic-induced hypertension treatment (iHTN) is helpful for alleviating early neurological deterioration (END) in acute small vessel occlusive stroke. We examined the time parameters related to iHTN effectiveness in these patients. METHODS: We retrospectively reviewed patients with acute small vessel occlusive stroke who underwent iHTN for END, defined as an increase of ≥2 points in total National Institutes of Health Stroke Scale (NIHSS) score or ≥1 point in motor items of NIHSS. The primary outcome was an early neurological improvement (ENI; a decrease of ≥2 points in total NIHSS score or ≥1 point in motor items of NIHSS), and the secondary outcome was any neurological improvement (a decrease of ≥1 point in the total NIHSS score). We conducted a multivariable logistic regression analysis, adjusting for demographics, risk factors, baseline clinical status, and intervention-related variables. We also generated a restricted cubic spline curve for the END-to-iHTN time cutoff. RESULTS: Among the 1062 patients with small vessel occlusive stroke screened between 2017 and 2021, 136 patients who received iHTN within 24 hours from END were included. The mean age was 65.1 (±12.0) years, and 61.0% were male. Sixty-five (47.8%) patients showed ENI and 77 (56.6%) patients showed any neurological improvement. END-to-iHTN time was significantly shorter in patients with ENI (150 [49–322] versus 290 [97–545] minutes; P =0.018) or any neurological improvement (150 [50–315] versus 300 [130–573] minutes; P =0.002). A 10-minute increase in the time between END and iHTN decreased the odds of achieving ENI (odds ratio, 0.984 [95% CI, 0.970–0.997]; P =0.019) or any neurological improvement (odds ratio, 0.978 [95% CI, 0.964–0.992]; P =0.002). The restricted cubic spline curve showed that the odds ratio of ENI reached its minimum at ≈3 hours. CONCLUSIONS: Among patients with small vessel occlusive stroke with END, a shorter interval between END and the initiation of iHTN was associated with increased odds of achieving neurological improvement. The efficacy of iHTN may be limited to induction within the first 3 hours of END.
- 1 January 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (1) , 14-21
Time Window for Induced Hypertension in Acute Small Vessel Occlusive Stroke With Early Neurological Deterioration
BACKGROUND: Therapeutic-induced hypertension treatment (iHTN) is helpful for alleviating early neurological deterioration (END) in acute small vessel occlusive stroke. We examined the time parameters related to iHTN effectiveness in these patients. METHODS: We retrospectively reviewed patients with acute small vessel occlusive stroke who underwent iHTN for END, defined as an increase of ≥2 points in total National Institutes of Health Stroke Scale (NIHSS) score or ≥1 point in motor items of NIHSS. The primary outcome was an early neurological improvement (ENI; a decrease of ≥2 points in total NIHSS score or ≥1 point in motor items of NIHSS), and the secondary outcome was any neurological improvement (a decrease of ≥1 point in the total NIHSS score). We conducted a multivariable logistic regression analysis, adjusting for demographics, risk factors, baseline clinical status, and intervention-related variables. We also generated a restricted cubic spline curve for the END-to-iHTN time cutoff. RESULTS: Among the 1062 patients with small vessel occlusive stroke screened between 2017 and 2021, 136 patients who received iHTN within 24 hours from END were included. The mean age was 65.1 (±12.0) years, and 61.0% were male. Sixty-five (47.8%) patients showed ENI and 77 (56.6%) patients showed any neurological improvement. END-to-iHTN time was significantly shorter in patients with ENI (150 [49–322] versus 290 [97–545] minutes; P =0.018) or any neurological improvement (150 [50–315] versus 300 [130–573] minutes; P =0.002). A 10-minute increase in the time between END and iHTN decreased the odds of achieving ENI (odds ratio, 0.984 [95% CI, 0.970–0.997]; P =0.019) or any neurological improvement (odds ratio, 0.978 [95% CI, 0.964–0.992]; P =0.002). The restricted cubic spline curve showed that the odds ratio of ENI reached its minimum at ≈3 hours. CONCLUSIONS: Among patients with small vessel occlusive stroke with END, a shorter interval between END and the initiation of iHTN was associated with increased odds of achieving neurological improvement. The efficacy of iHTN may be limited to induction within the first 3 hours of END.